Keyword Connections

antiviral agents / adverse effects

Journals

0

No Journal Connected

Research Groups

0

No Research Group Connected

Bibliographies

13

1 [COVID-19: a cardiological point-of-view]

2 Telaprevir for previously untreated chronic hepatitis C virus infection

3 Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment

4 Boceprevir for untreated chronic HCV genotype 1 infection

5 Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial

6 Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study

7 Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis

8 Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial

9 Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

10 Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

11 Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

12 Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses

13 Sofosbuvir for previously untreated chronic hepatitis C infection